1179-9889

Blood and Lymphatic Cancer Targets and Therapy

Dove Medical Press

View prefix report (10.2147)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 144 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact144 DOIs
2

Attach ORCID iDs across 88 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact88 DOIs
3

Deposit reference lists for 76 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact76 DOIs

DOIs for this ISSN

Showing the top 5 of 143 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Managing treatment-related peripheral neuropathy in patients… (10.2147/blctt.s91251)
Abstract References ORCID
117.62 36
2 Recent advances in the biology and treatment of B-cell acute… (10.2147/blctt.s170351)
Abstract References ORCID
109.68 28
3 Plasmablastic lymphoma: current perspectives (10.2147/blctt.s142814)
Abstract References
94.32 76
4 Role of L-asparaginase in acute lymphoblastic leukemia: focu… (10.2147/blctt.s18699)
Abstract References ORCID
92.28 16
5 Uptake of lymphoma-derived exosomes by peripheral blood leuk… (10.2147/blctt.s130826)
Abstract References ORCID
85.96 13
6 Blastic plasmacytoid dendritic cell neoplasm: challenges and… (10.2147/blctt.s132060)
Abstract References ORCID
85.96 13
7 Smoldering multiple myeloma: prevalence and current evidence… (10.2147/blctt.s136447)
Abstract References ORCID
85.96 13
8 CAR T-Cell Therapy for Patients with Multiple Myeloma: Curre… (10.2147/blctt.s327016)
Abstract ORCID
84.06 47
9 <p>The expanding role of venetoclax in chronic lymphoc… (10.2147/blctt.s177009)
Abstract References ORCID
80.94 11
10 <p>Prognostic analysis of CD5 expression in double-hit… (10.2147/blctt.s216292)
Abstract References ORCID
78.10 10
11 Optimal management of endemic Burkitt lymphoma: a holistic a… (10.2147/blctt.s67769)
Abstract References ORCID
78.10 10
12 <p>IDH1-mutated relapsed or refractory AML: current ch… (10.2147/blctt.s177913)
Abstract References
73.12 28
13 <p>Evaluating Blinatumomab for the Treatment of Relaps… (10.2147/blctt.s223894)
Abstract ORCID
73.12 28
14 Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small… (10.2147/blctt.s326627)
Abstract ORCID
69.01 23
15 Advances in the pathophysiology and treatment of relapsed/re… (10.2147/blctt.s105458)
Abstract References ORCID
67.73 7
16 Waldenström macroglobulinemia: biology, genetics, a… (10.2147/blctt.s84157)
Abstract References ORCID
67.73 7
17 <p>Knockout Of <em>BIRC5</em> Gene By CRIS… (10.2147/blctt.s230383)
Abstract References
67.12 21
18 Complications and management of coagulation disorders in leu… (10.2147/blctt.s125121)
Abstract References
60.21 15
19 Differential Diagnosis and Therapeutic Advances in Multiple… (10.2147/blctt.s272703)
Abstract ORCID
58.80 14
20 Spotlight on ponatinib in the treatment of chronic myeloid l… (10.2147/blctt.s130197)
Abstract References ORCID
58.36 5
21 Treatment strategies for patients with diffuse large B-cell… (10.2147/blctt.s18701)
Abstract References ORCID
58.36 5
22 Efficacy and Safety Profile of Ivosidenib in the Management… (10.2147/blctt.s236446)
Abstract ORCID
57.31 13
23 <p>Strategies For Targeting Chronic Myeloid Leukaemia… (10.2147/blctt.s228815)
Abstract References
55.70 12
24 <p>The Evolving Role of Brentuximab Vedotin in Classic… (10.2147/blctt.s231821)
Abstract References
55.70 12
25 Profile of elotuzumab and its potential in the treatment of… (10.2147/blctt.s49780)
Abstract References ORCID
52.42 4
26 Idelalisib therapy of indolent B-cell malignancies: chronic… (10.2147/blctt.s73530)
Abstract References ORCID
52.42 4
27 Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma (10.2147/blctt.s407086)
Abstract ORCID
47.71 8
28 Advances in the diagnosis and management of lymphoma (10.2147/blctt.s15554)
Abstract References ORCID
45.15 3
29 Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehen… (10.2147/blctt.s426588)
Abstract ORCID
45.15 7
30 HIV/AIDS Associated Lymphoma: Review (10.2147/blctt.s361320)
Abstract
44.27 58
31 Asparaginase in the Treatment of Acute Lymphoblastic Leukemi… (10.2147/blctt.s342052)
Abstract
43.31 53
32 Clinical Utility of Pegaspargase in Children, Adolescents an… (10.2147/blctt.s245210)
Abstract
40.58 41
33 Current understanding of the role and regulation of miRNAs i… (10.2147/blctt.s129618)
Abstract References
38.91 5
34 FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem… (10.2147/blctt.s281252)
Abstract ORCID
38.91 5
35 Impact of obinutuzumab alone and in combination for follicul… (10.2147/blctt.s114173)
Abstract References ORCID
35.78 2
36 The evaluation and optimal use of rituximab in lymphoid mali… (10.2147/blctt.s15561)
Abstract References ORCID
35.78 2
37 Trends in the treatment of cutaneous T-cell lymphoma &nd… (10.2147/blctt.s15564)
Abstract References ORCID
35.78 2
38 Mantle cell leukemia as a cause of leukostasis (10.2147/blctt.s17157)
Abstract References ORCID
35.78 2
39 Leptomeningeal myelomatosis in previously treated high-risk… (10.2147/blctt.s22703)
Abstract References ORCID
35.78 2
40 Recent developments in myelofibrosis (10.2147/blctt.s24960)
Abstract References ORCID
35.78 2
41 Emerging targets in human lymphoma: targeting the MYD88 muta… (10.2147/blctt.s35292)
Abstract References ORCID
35.78 2
42 Developments in anaplastic large-cell lymphoma: targeting th… (10.2147/blctt.s35349)
Abstract References ORCID
35.78 2
43 Profile of inotuzumab ozogamicin and its potential in the tr… (10.2147/blctt.s49048)
Abstract References ORCID
35.78 2
44 Splenic marginal zone lymphoma: a review of the clinical pre… (10.2147/blctt.s49373)
Abstract References ORCID
35.78 2
45 MicroRNAs as B-cell lymphoma biomarkers (10.2147/blctt.s60481)
Abstract References ORCID
35.78 2
46 Activation of wild-type p53 by MDM2 inhibitors: a new strate… (10.2147/blctt.s60486)
Abstract References ORCID
35.78 2
47 Outcomes and relapse patterns following chemotherapy in adva… (10.2147/blctt.s160404)
Abstract References
34.95 4
48 <p>Strategies for minimal residual disease detection:… (10.2147/blctt.s172693)
Abstract References
34.95 4
49 BCL2 Family Inhibitors in the Biology and Treatment of Multi… (10.2147/blctt.s245191)
Abstract
34.04 22
50 PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise (10.2147/blctt.s309171)
Abstract
33.06 20